SH3BGR Antibody

What is SH3BGR and what cellular functions does it perform?

SH3BGR (SH3 domain-binding glutamic acid-rich protein) is a protein-coding gene that plays significant roles in cellular signaling pathways. It functions primarily through SH3/SH2 adaptor activity and is involved in positive regulation of signal transduction and protein complex assembly . The protein is particularly known for its interactions within the cytosol, where it participates in various cellular processes. Research has shown that SH3BGR is part of important regulatory mechanisms that influence cell migration and angiogenesis, suggesting its potential role in both normal physiological processes and pathological conditions .

How should researchers distinguish between SH3BGR and related family proteins?

When conducting research on SH3BGR, it's essential to distinguish it from other members of the same protein family, particularly SH3BGRL3. Though they share nomenclature similarities, these proteins have distinct functions and characteristics:

SH3BGR contains a canonical SH3 binding domain sequence (PLPPQIF), while SH3BGRL3 displays only a partial sequence (PPQIV) . Additionally, SH3BGR shows selective expression in muscle tissues, whereas SH3BGRL3 is ubiquitously expressed across various tissues . Understanding these distinctions is crucial for proper experimental design and interpretation of results.

What experimental applications are most suitable for SH3BGR antibody use?

Based on validated research applications, SH3BGR antibodies are suitable for multiple experimental techniques. The primary applications include:

• Western Blotting (WB): Effective at dilutions of 1:500-1:2000, with optimal detection in muscle tissues

• Immunohistochemistry (IHC): Recommended at dilutions of 1:20-1:200, with particularly good results in heart and skeletal muscle tissues

• Immunofluorescence (IF/ICC): Functional at dilutions of 1:200-1:800 in cellular systems

• ELISA: Validated for detection of recombinant and native SH3BGR protein

When designing experiments, researchers should consider that antigen retrieval methods significantly impact antibody performance in IHC applications. For optimal results with SH3BGR antibodies, TE buffer at pH 9.0 is recommended, though citrate buffer at pH 6.0 may serve as an alternative .

How does the SH3BGR/STAT3 pathway regulate cell migration and angiogenesis?

The SH3BGR/STAT3 signaling axis represents a critical regulatory mechanism for cellular migration and angiogenesis. Research has demonstrated that disruption of SH3BGR expression can significantly alter these cellular processes. In particular, viral microRNAs targeting SH3BGR have been shown to promote cell migration and angiogenesis .

The mechanism involves:

• Regulation of SH3BGR expression, which normally functions as a modulator of STAT3 signaling

• When SH3BGR is downregulated (as through viral miRNA targeting), STAT3 activity increases

• Enhanced STAT3 signaling promotes cellular migration pathways and angiogenic processes

This pathway has been specifically observed in the context of gammaherpesvirus infection, where viral miR-K6-3p directly targets the SH3BGR 3'UTR in a dose-dependent manner . The specificity of this interaction was confirmed through multiple lines of evidence, including 3'UTR luciferase reporter assays and mutational studies that identified the precise binding site in the SH3BGR 3'UTR .

What methodologies effectively demonstrate SH3BGR targeting by miRNAs?

Researchers investigating miRNA-mediated regulation of SH3BGR should consider multiple complementary approaches to establish targeting specificity:

• 3'UTR Luciferase Reporter Assays: This serves as the primary method to confirm direct targeting. Construct a reporter containing the SH3BGR 3'UTR downstream of a luciferase gene and measure luciferase activity in the presence of varying concentrations of the candidate miRNA. A dose-dependent decrease in reporter activity indicates targeting .

• Site-Directed Mutagenesis Validation: To confirm binding site specificity:

  • Mutate the putative miRNA binding site in the SH3BGR 3'UTR

  • Test the mutant 3'UTR in reporter assays with wild-type miRNA

  • Design complementary miRNA mutants that match the 3'UTR mutations

  • Demonstrate restored inhibition with matching mutant pairs

• Protein Expression Analysis: Western blotting to demonstrate that miRNA introduction leads to decreased SH3BGR protein expression in a dose-dependent manner .

• Comparative Analysis with Natural Systems: Compare SH3BGR expression levels in cells transfected with miRNA mimics versus naturally infected cells to establish physiological relevance .

How does SH3BGR function in cell-type specific contexts?

SH3BGR exhibits significant cell-type specificity in both expression and function. While the protein shows particularly high expression in muscle tissues such as heart and skeletal muscle , its functional impact extends to various cellular contexts:

• Endothelial Cells: In human umbilical vein endothelial cells (HUVEC), SH3BGR regulates angiogenic processes, with its downregulation promoting increased vessel formation .

• Muscle Tissue: The high expression in cardiac and skeletal muscle suggests tissue-specific functions that may relate to specialized contractile or signaling properties .

• Role in Cancer Contexts: Though less directly studied than its family member SH3BGRL3, the SH3BGR/STAT3 pathway appears relevant to processes that influence tumor progression, particularly through effects on cell migration and angiogenesis .

When designing studies to investigate SH3BGR function, researchers should carefully consider cellular context and select appropriate cell types based on their specific research questions. For muscle-specific functions, primary muscle cells or relevant cell lines would be most appropriate, while endothelial models would better serve angiogenesis studies.

What are the critical considerations for SH3BGR antibody validation?

Thorough validation of SH3BGR antibodies is essential for generating reliable research data. A comprehensive validation approach should include:

• Specificity Testing:

  • Western blot analysis using tissues known to express SH3BGR (heart and skeletal muscle) versus negative control tissues

  • Testing in knockout/knockdown systems where available

  • Peptide competition assays to confirm epitope specificity

• Application-Specific Validation:

  • For IHC applications: Test multiple antigen retrieval methods, as SH3BGR detection is significantly improved with TE buffer pH 9.0 compared to citrate buffer pH 6.0

  • For IF applications: Include co-localization studies with known markers to confirm expected subcellular distribution

  • For WB applications: Verify the detection of the expected molecular weight (26-30 kDa)

• Cross-Reactivity Assessment:

  • Evaluate potential cross-reactivity with other SH3BGR family members

  • Test antibody performance across multiple species when working with non-human models (note: current antibodies show reactivity with human and mouse samples)

What factors influence detection of proper SH3BGR molecular weight in western blotting?

Researchers sometimes observe variable molecular weights for SH3BGR in western blotting experiments. The calculated molecular weight of SH3BGR is 26 kDa, but observed weights typically range between 26-30 kDa . Several factors can account for these variations:

• Post-translational Modifications: SH3BGR may undergo modifications that alter its migration pattern, including:

  • Phosphorylation events that can add approximately 0.5-1 kDa per phosphate group

  • Glycosylation or other covalent modifications

• Sample Preparation Variables:

  • Incomplete denaturation can result in aberrant migration

  • Reducing vs. non-reducing conditions can affect protein conformation

  • Buffer composition, particularly salt concentration and detergents

• Tissue-Specific Variations:

  • Different isoforms or splice variants may be expressed in different tissues

  • Tissue-specific post-translational modifications

For optimal detection, researchers should use freshly prepared samples, ensure complete denaturation, and include positive control samples from tissues known to express SH3BGR (heart and skeletal muscle) .

How should researchers design experiments to investigate SH3BGR-protein interactions?

To rigorously characterize SH3BGR protein interactions, multiple complementary approaches should be employed:

• Co-immunoprecipitation (Co-IP) Studies:

  • Use epitope-tagged SH3BGR constructs (e.g., FLAG-SH3BGR) for improved detection

  • Include appropriate negative controls (empty vector transfections)

  • Perform reciprocal Co-IPs using the putative binding partner as bait

  • Consider both endogenous protein interactions and overexpression systems

• Microscopy-Based Approaches:

  • Confocal microscopy to assess co-localization patterns

  • Proximity ligation assays for higher sensitivity detection of protein-protein interactions

  • FRET or BRET approaches to assess direct interactions in living cells

• Validation Through Mutational Analysis:

  • Generate domain deletion mutants to identify specific interaction regions

  • Create point mutations at predicted binding interfaces

  • Test interaction strength using quantitative approaches like microscale thermophoresis

When analyzing results, researchers should be cautious about indirect interactions. For example, the search results indicate that while co-localization may be observed between certain proteins, direct binding may not occur . Mass spectrometry analysis following co-immunoprecipitation can help identify components of larger protein complexes.

How can researchers address non-specific binding issues with SH3BGR antibodies?

Non-specific binding is a common challenge when working with antibodies. For SH3BGR antibodies, consider these troubleshooting approaches:

• Optimizing Blocking Conditions:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Increase blocking time or blocking agent concentration

  • For tissue samples, consider adding species-specific serum to blocking buffer

• Adjusting Antibody Parameters:

  • Titrate antibody concentrations (typical working dilutions range from 1:500-1:2000 for WB and 1:20-1:200 for IHC)

  • Reduce primary antibody incubation time or temperature

  • Increase washing steps between antibody incubations

• Sample-Specific Optimizations:

  • For IHC/IF applications, adjust antigen retrieval methods (SH3BGR detection is improved with TE buffer pH 9.0)

  • For WB applications, modify buffer components or detergent concentrations

  • Consider pre-adsorption of antibodies with non-specific proteins

If non-specific binding persists, verify antibody specificity using additional approaches such as immunoprecipitation followed by mass spectrometry or testing in SH3BGR-depleted samples.

What controls are essential when studying SH3BGR in experimental systems?

Proper experimental controls are crucial for generating reliable data on SH3BGR function and expression:

• Positive Controls:

  • Include samples from tissues known to express SH3BGR (heart and skeletal muscle)

  • Use cells transfected with SH3BGR expression constructs

  • Consider commercially available recombinant SH3BGR protein

• Negative Controls:

  • Tissues or cells lacking SH3BGR expression

  • SH3BGR-knockdown or knockout samples where available

  • Isotype control antibodies for immunodetection applications

  • Secondary antibody-only controls to assess non-specific binding

• Specificity Controls:

  • Peptide competition assays using immunizing peptide

  • Testing multiple antibodies targeting different epitopes

  • Including closely related family members (e.g., SH3BGRL3) to assess cross-reactivity

• Functional Controls:

  • When studying SH3BGR-dependent processes, include both gain-of-function (overexpression) and loss-of-function (knockdown) approaches

  • For miRNA targeting studies, include both wild-type and mutant constructs

How should researchers interpret conflicting data regarding SH3BGR function in different experimental systems?

When faced with conflicting results regarding SH3BGR function, consider these interpretive approaches:

• Cell Type-Specific Differences:

  • SH3BGR shows tissue-specific expression patterns, primarily in muscle tissues

  • Different cell types may express different SH3BGR binding partners

  • Signaling pathway components may vary across cell types

• Methodological Variations:

  • Different detection methods have varying sensitivities and specificities

  • Antibody epitope accessibility may differ between applications

  • Sample preparation methods can affect protein detection

• Contextual Dependencies:

  • SH3BGR function may depend on specific cellular conditions or stimuli

  • Interaction with STAT3 pathway suggests context-dependent signaling roles

  • Post-translational modifications may alter protein function

• Experimental Validation Approaches:

  • Repeat experiments using multiple methodologies

  • Perform dose-response studies to identify threshold effects

  • Consider temporal dynamics of SH3BGR activity

  • Test in physiologically relevant models that better recapitulate in vivo conditions

Remember that seemingly conflicting data may actually reveal important biological complexities rather than experimental errors. Careful documentation of all experimental conditions is essential for proper interpretation.

What are promising approaches for studying SH3BGR in disease models?

Based on current knowledge about SH3BGR function, several research directions hold particular promise:

• Cardiovascular Disease Models:

  • Given the high expression in heart tissue , investigate SH3BGR's role in cardiac pathologies

  • Explore potential contributions to cardiomyocyte function and cardiac remodeling

  • Consider genetic approaches in animal models using tissue-specific manipulations

• Cancer Research Applications:

  • Further examine the SH3BGR/STAT3 pathway in tumor angiogenesis

  • Investigate whether SH3BGR status correlates with cancer progression or metastasis

  • Explore potential as a biomarker or therapeutic target

• Viral Pathogenesis Studies:

  • Expand research on viral targeting of SH3BGR beyond gammaherpesviruses

  • Determine whether SH3BGR targeting is a common viral strategy

  • Develop interventions to protect SH3BGR from viral-mediated downregulation

Regardless of the disease context, researchers should consider both genetic and pharmacological approaches to manipulate SH3BGR levels or function, and incorporate both in vitro and in vivo models for comprehensive analysis.

How can advanced technologies enhance SH3BGR research?

Emerging technologies offer powerful new approaches for studying SH3BGR:

• CRISPR/Cas9 Applications:

  • Generate precise knockouts or knock-ins to study SH3BGR function

  • Create tagged endogenous versions for improved detection

  • Develop inducible or tissue-specific SH3BGR manipulation systems

• Single-Cell Analysis:

  • Examine SH3BGR expression heterogeneity within tissues

  • Correlate SH3BGR levels with specific cellular phenotypes

  • Identify novel cell populations with unique SH3BGR-dependent characteristics

• Structural Biology Approaches:

  • Determine high-resolution structures of SH3BGR in complex with binding partners

  • Identify critical interaction domains for targeted disruption

  • Design structure-based modulators of SH3BGR function

• Systems Biology Integration:

  • Incorporate SH3BGR into broader signaling network models

  • Use computational approaches to predict context-dependent functions

  • Identify potential cooperative or compensatory mechanisms involving other family members

These advanced technologies can help resolve current knowledge gaps and accelerate discovery of SH3BGR's functional roles in both normal physiology and disease states.